Latest news with #AlkemLaboratories'
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Alkem Labs Q1 profit rises 22% to ₹664 cr on India, overseas sales growth
Alkem Laboratories on Tuesday reported a 22 per cent year-on-year (Y-o-Y) rise in its consolidated net profit for the June quarter (Q1FY26) to ₹664.3 crore, up from ₹545.2 crore in the same period last year. Revenue from operations increased 11.2 per cent Y-o-Y to ₹3,371 crore in Q1FY26 from ₹3,031 crore in Q1FY25. The company attributed this growth to strong sales in both India and international markets. Commenting on the performance, Vikas Gupta, Chief Executive Officer of Alkem, said Q1FY26 marked a strong start to the year, with healthy growth across both domestic and overseas markets. India sales grew 12 per cent Y-o-Y to ₹2,265 crore in the June quarter, while international sales rose 8.9 per cent to ₹1,054 crore, contributing 31.7 per cent to overall revenue. In the international business, the United States market recorded sales of ₹698 crore, up 8.8 per cent from ₹641.6 crore a year earlier, contributing 21 per cent to total sales. Sales from other international markets — including Latin America, Australia, and Europe — rose 9.1 per cent to ₹355.6 crore, contributing 10.7 per cent to revenue. Gupta said the company is strategically accelerating its focus on the non-US business segment by strengthening its presence in high-potential markets and capturing new opportunities aligned with Alkem's long-term growth ambitions. Alkem also announced it will incorporate a Saudi Arabia-based subsidiary, holding a 51 per cent stake. 'The subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing, and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia,' the company said in a filing to the exchanges. On Tuesday, Alkem Laboratories' share price rose 6.7 per cent to close at ₹5,167 on the Bombay Stock Exchange (BSE).
Business Upturn
3 days ago
- Business
- Business Upturn
Alkem Laboratories shares jump 6% on strong Q1 results
Alkem Laboratories' stock jumped over 6% after the pharma major delivered an impressive set of numbers for the quarter ended June 30, 2025, driven by robust domestic and international performance. As of 1:46 PM, the shares were trading 6.04% higher at Rs 5,137.00. The company's consolidated net profit rose 21.45% year-on-year to ₹668 crore, compared to ₹550 crore in the same period last year. Revenue climbed 11.2% to ₹3,371 crore from ₹3,031.8 crore, while EBITDA grew 21.35% to ₹739 crore, up from ₹609 crore a year ago. Margins also improved to 21.9%, against 20% in the previous year, reflecting operational efficiency. Domestic market The domestic formulations business remained Alkem's biggest revenue contributor, generating ₹2,265 crore in sales — a 12% YoY increase and accounting for 68.3% of the company's total revenue. As per IQVIA (SSA) data, Alkem outperformed the Indian Pharmaceutical Market (IPM) in seven key therapies — Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology — growing at 1.1x to 2.3x the market rate. International market International sales rose 8.9% YoY to ₹1,053.9 crore. The US business, which contributes 21% to total sales, clocked ₹698.2 crore, up 8.8% from last year. Non-US international markets brought in ₹355.6 crore, marking a 9.1% increase and contributing 10.7% to total revenue. In the US market, Alkem made significant strides, including filing its first Biologics License Application (BLA), securing five Abbreviated New Drug Application (ANDA) approvals (two tentative), and launching three new products during the quarter. As of June 30, 2025, the company had filed 185 ANDAs, two New Drug Applications (NDAs), and one BLA with the USFDA, with approvals for 160 ANDAs (including 15 tentative) and both NDAs. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash
